13 stories mentioning HKG:2617Updated 4d ago
Every FINWIRES story that references HKG:2617, newest first.
TransThera Sciences (Nanjing) (HKG:2617) dosed the first patient in a phase II clinical trial of tinengotinib in China, according to a Friday Hong Kong bourse filing.The trial is testing the safety and efficacy of the drug in combination with novel hormonal therapy for pretreated and progressed metastatic castration-resistant prostate cancer.
TransThera Sciences (Nanjing)'s (HKG:2617) Yochanra has been included in the Chinese Society of Clinical Oncology's guidelines for the diagnosis and treatment of biliary tract cancers.The inclusion is for the drug as a Class II recommendation Class 2A for the treatment of advanced biliary tract cancers, a Friday bourse filing showed.
TransThera Sciences (Nanjing) (HKG:2617) said China's National Medical Products Administration granted conditional marketing approval for Yochanra (Tinengotinib tablets) to treat adults with unresectable advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement.The approval covers patients who have received prior systemic therapy and FGFR inhibitor treatment, according to a Thursday Hong Kong bourse filing.
TransThera Sciences (HKG:2617) said China's National Medical Products Administration approved a Phase 2 clinical trial of its TT-00973 tablets in combination with firmonertinib mesylate, according to a July 10 Hong Kong bourse filing.The combination will be evaluated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR-sensitive mutations.The multi-center, open-label study will assess the safety and efficacy of the combination therapy.
TransThera Sciences (Nanjing) (HKG:2617) obtained approval for a phase II trial of TT-01488 tablets, according to a Wednesday Hong Kong bourse filing.The drug will be tested in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma.
TransThera Sciences (Nanjing) (HKG:2617) completed enrollment for a phase III trial of Tinengotinib.The drug is being tested for the treatment of patients with advanced cholangiocarcinoma, according to a Wednesday Hong Kong bourse filing.
TransThera Sciences (Nanjing) (HKG:2617) said it completed a HK$156.6 million share offering, according to a Wednesday filing with the Hong Kong bourse.The drugmaker's shares fell over 5% in late morning trade Thursday.The company sold 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product, tinengotinib.The shares represent 1.23% of the company's existing H shares and 0.94% of its enlarged share capital.
TransThera Sciences (Nanjing) (HKG:2617) said Chinese regulators approved its phase 2 clinical trial of tinengotinib to treat prostate cancer, according to a Tuesday filing with the Hong Kong bourse.The company's shares fell over 3% in afternoon trade Wednesday.The firm will evaluate a combination of tinengotinib and novel hormone therapy in an open-label study in subjects with metastatic castration-resistant prostate cancer.In a separate announcement, the firm said it is partnering with Shanghai Allist Pharmaceuticals on another open-label phase 2 study to evaluate TT-00973-MS tablets in combination with firmonertinib mesylate tablets in patients with locally advanced or metastatic non-small cell lung cancer.Based on the results of the study, the parties may collaborate on a phase 3 study.
TransThera Sciences (Nanjing) (HKG:2617) said it was looking to raise HK$156.6 million via a share offering, according to a Tuesday filing with the Hong Kong bourse.The drugmaker is seeking investors for 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product tinengotinib.The shares represent 1.24% of the company's existing H shares and 0.95% of its total issued shares, and 1.23% and 0.94% as enlarged by the offering, respectively.TransThera recently said that tinengotinib was found to offer benefit to patients in a clinical trial conducted in China.Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.
TransThera Sciences (Nanjing) (HKG:2617) said its anti-tumor drug candidate, tinengotinib, was found to offer benefit to patients in a clinical trial conducted in China, according to a Sunday filing with the Hong Kong bourse.Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.Subjects who received tinengotinib as a monotherapy achieved an objective response rate of 16.7%, while those in the combination arm had an ORR of 22.6%, the firm said.
TransThera Sciences (Nanjing) (HKG:2617) completed the placing of nearly 5.1 million shares to at least six investors at a net issue price of HK$55.49 apiece to raise net proceeds HK$282.2 million, according to a Tuesday Hong Kong bourse filing.The shares represent 1.65% of the clinical-stage biopharmaceutical firm's issued Hong Kong-listed shares and 1.26% of its total issued share capital as enlarged by the placing.The firm will use proceeds for research and development, the manufacturing and commercialization of core product Tinengotinib in China, and working capital and general corporate purposes.
TransThera Sciences (Nanjing) (HKG:2617) dosed the first patient in a confirmatory phase III clinical trial of Tinengotinib, according to a Friday Hong Kong bourse filing.The drug is being tested as a monotherapy for the treatment of patients with advanced cholangiocarcinoma, the clinical-stage biopharmaceutical firm said.
TransThera Sciences (Nanjing) (HKG:2617) plans to raise about HK$282.2 million in net proceeds through a share placement, according to a Wednesday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm agreed to place 5.1 million shares at HK$57.03 each to at least six independent investors.The placing price represents a discount of about 18% to the last closing price and about 19.2% to the five-day average price, the filing said.The placing shares represent about 1.3% of the company's existing issued share capital.Net proceeds will be used mainly for research and development and commercialization of its core product, Tinengotinib, as well as working capital.
